Pfizer expects patent losses to hurt bottom line

Share this article:
Patent expirations on over a half-dozen of its best selling drugs has Pfizer bracing itself for substantial pressure on its earnings in the years 2005-2007, the company said in a presentation to financial analysts this week.
Pfizer said drugs that it markets that face patent expirations represent $14 billion in sales, approximately one-fourth of the company's annual revenue. The company outlined its pipeline during a presentation held Tuesday at company research facilities in Groton, Conn.
Although the company did not make a forecast for 2005, Pfizer said its financial results next year will be hurt by generic competition for its anti-fungal indication Diflucan, epilepsy drug Neurontin, antibiotic Zithromax and hypertension drug Accupril.
The company also is preparing for the loss of U.S. marketing exclusivity on the allergy drug Zyrtec and anti-depressant Zoloft in 2006 and hypertension drug Norvasc in 2007.
"From a revenue standpoint, they're not going to make up for those lost revenues in the next three years," Deutsche Bank analyst Barbara Ryan told Reuters.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...